In Brief: Allergan's Acular
Executive Summary
Allergan's Acular: Dosing period of ketorolac .5% ophthalmic solution for relief of ocular itching due to seasonal allergic rhinitis is extended beyond one week by FDA's Sept. 18 approval of NDA 19-700/S-003 and S-004. FDA also approves a 10 mL fill size of Acular to join the 3 mL and 5 mL sizes. FDA's approval letter notes that a contraindication against use "while wearing soft contact lenses" will be removed, to be replaced by a similar statement in the "precautions" section of labeling...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth